Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Flinn, I. W.
Right arrow Articles by Byrd, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flinn, I. W.
Right arrow Articles by Byrd, J. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:691-695, 2000
© 2000 European Society for Medical Oncology

research-article

A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL

I. W. Flinn1,, S. N. Goodman1, L. Post1, J. Jamison2, C. B. Miller1, S. Gore1, L. Diehl2, C. Willis2, R. F. Ambinder1 and J. C. Byrd1,2

1The Johns Hopkins University Baltimore, Maryland
2Walter Reed Army Medical Center Washington DC, USA

Correspondence to: I. W. Flinn, MD, John Hopkins Oncology Center, Cancer Research Building, Room 388, 1650 Orleans, Baltimore, Maryland 21231, USA, E-mail: iflinn{at}jhmi.edu

Background: Standard therapy for lymphoma consists of a cyclophosphamide (C), doxorubicin, vincristine (V), and prednisone (P) (CHOP) combination regimen. Liposomal daunorubicin (DaunoXome®) is an alternative to doxorubicin for patients with lymphoma because of its more favorable safety profile and potentially more selective uptake in lymphoma. The objectives of this study were to determine the maximum tolerated dose (MTD) of liposomal daunorubucin with CVP (COP-X) and the tolerability of the regimen in patients with indolent lymphoma.

Patients and methods: Patients with low-grade and intermediate-grade lymphoma having adequate cardiac, hepatic, and renal function were enrolled. Patients received C 750 mg/m2, V 1.4 mg/m2 (maximum 2.0 mg), and liposomal daunorubicin 50–100 mg/m2 i.v. on day 1 and P 100 mg p.o. on days 1–5. MTD was the liposomal daunorubicin dose associated with 20% dose-limiting toxicity (ANC < 500/mm3 for > 5 days or febrile neutropenia).

Results: Twenty patients, median age 59 years, were treated. The liposomal daunorubicin MTD combined with CVP was 70–80 mg/m2, depending on patient population. No significant non-hematologic toxicity occurred. Response rate was 44% (2 complete and 5 partial responses).

Conclusions: A liposomal daunorubicin dose of 80 mg/m2in the COP-X regimen was well tolerated with little non-hematologic toxicity.

anthracycline, chemotherapy, liposomal daunorubicin, lymphoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.